|
業務類別
|
Biotechnology |
|
業務概覽
|
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operationsas a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. |
| 公司地址
| 234 Church Street, Suite 1020, New Haven, CT, USA, 06510 |
| 電話號碼
| +1 203 859-3820 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.rallybio.com |
| 員工數量
| 25 |
| Mr. Jonathan I. Lieber, M.B.A. |
Principal Accounting Officer, Chief Financial Officer and Treasurer |
美元 478.40K |
16/03/2026 |
| Dr. Stephen Uden, M.D. |
Chief Executive Officer, President and Director |
美元 551.20K |
16/03/2026 |
|
|
| Dr. Martin W. Mackay, PhD |
Chairman of the Board |
16/03/2026 |
| Dr. Stephen Uden, M.D. |
Chief Executive Officer, President and Director |
16/03/2026 |
| Mr. Ronald M. Hunt, M.B.A. |
Independent Director |
16/03/2026 |
| Dr. Robert Hopfner, M.B.A.,PhD |
Independent Director |
16/03/2026 |
| Ms. Christine A. Nash, M.B.A. |
Independent Director |
16/03/2026 |
| Ms. Paula Soteropoulos |
Lead Independent Director |
16/03/2026 |
| Ms. Helen M. Boudreau, M.B.A. |
Independent Director |
16/03/2026 |
| Dr. Hui Liu, M.B.A.,PhD |
Independent Director |
16/03/2026 |
| Dr. Lucian Iancovici, M.D. |
Independent Director |
16/03/2026 |
| Dr. Wendy K. Chung, M.D.,PhD |
Independent Director |
16/03/2026 |
|
|
|
|
